We serve (R)-(+)-2-Tetrahydrofuroic acid CAS:87392-05-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
| Items of Analysis | Standard of Analysis | Test Results |
| Appearance | Colorless to light yellow viscous liquid | Light yellow Viscous liquid |
| Specific Rotation | ≥ +21°(Chloroform 20 ℃) | +24° |
| Water | ≤ 0.5% | 0.034% |
| Optial Purity | ≥ 95.0% e.e | 96.2% e.e |
| Assay | ≥ 99.0% | 99.5% |
| Conclusion | Conforms to Factory Standard | |
Contact us for information like (R)-(+)-2-Tetrahydrofuroic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(2R)-Tetrahydrofuran-2-carboxylic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-Furancarboxylic acid, tetrahydro-, (2R)- Use and application,2-Furancarboxylic acid, tetrahydro-, (2R)- technical grade,usp/ep/jp grade.
Related News: In 2016, in order to promote the innovative development, transformation and upgrading of the pharmaceutical industry, the Development and Reform Commission led the compilation of the “Guiding Opinions on Promoting the Healthy Development of the Pharmaceutical Industry”, which put forward requirements for all aspects of the medical industry and specifically proposed support for the field of chemical raw materials. .benzyl (3-fluoro-4-(4-methyl-3-oxopiperazin-1-yl)phenyl)carbamate manufacturer Also that day the CDC reported the first case of person-to-person transmission in Illinois between household members. Nitrogenase (uncultured cyanobacterium clone 5.317RT gene nifHfragment) supplier Also that day the CDC reported the first case of person-to-person transmission in Illinois between household members. (3-{4-[4-(1-Benzyl-1H-indazol-5-ylamino)-quinazolin-6-yl]-benzyl}-3-aza-bicyclo[3.1.0]hex-6-yl)-methanol vendor Further research on Oligomannate’s pharmacological mechanism and long-term safety and effectiveness is required, according to the NMPA statement.Further research on Oligomannate’s pharmacological mechanism and long-term safety and effectiveness is required, according to the NMPA statement.
